Abbott Laboratories (NYSE:ABT) – Equities research analysts at Gabelli issued their FY2017 EPS estimates for shares of Abbott Laboratories in a research note issued on Thursday. Gabelli analyst J. Tsai forecasts that the healthcare product maker will post earnings per share of $2.50 for the year. Gabelli also issued estimates for Abbott Laboratories’ FY2018 earnings at $2.80 EPS, FY2019 earnings at $3.15 EPS, FY2020 earnings at $3.55 EPS and FY2021 earnings at $3.95 EPS.

Other equities analysts also recently issued research reports about the stock. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research note on Monday, July 3rd. BidaskClub downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research note on Thursday, August 3rd. Guggenheim initiated coverage on shares of Abbott Laboratories in a research note on Thursday, June 29th. They issued a “buy” rating and a $58.00 price objective for the company. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 21st. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $56.81.

ILLEGAL ACTIVITY NOTICE: “Gabelli Weighs in on Abbott Laboratories’ FY2017 Earnings (ABT)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/23/gabelli-weighs-in-on-abbott-laboratories-fy2017-earnings-abt.html.

Shares of Abbott Laboratories (NYSE ABT) opened at 56.32 on Monday. The company’s 50-day moving average price is $53.27 and its 200 day moving average price is $48.51. Abbott Laboratories has a one year low of $37.38 and a one year high of $56.60. The stock has a market capitalization of $97.85 billion, a PE ratio of 78.88 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a return on equity of 14.50% and a net margin of 8.37%. Abbott Laboratories’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.59 EPS.

Institutional investors and hedge funds have recently made changes to their positions in the company. Heritage Trust Co grew its holdings in shares of Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares during the last quarter. Tributary Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the third quarter valued at $106,000. Winfield Associates Inc. grew its holdings in shares of Abbott Laboratories by 3.9% during the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after buying an additional 89 shares during the last quarter. Thompson Davis & CO. Inc. grew its holdings in shares of Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after buying an additional 370 shares during the last quarter. Finally, V Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the second quarter valued at $127,000. 71.45% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Stephen R. Fussell sold 196,550 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the sale, the insider now directly owns 221,488 shares of the company’s stock, valued at $10,963,656. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sharon J. Bracken sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total transaction of $98,320.00. Following the sale, the insider now directly owns 28,806 shares in the company, valued at $1,416,102.96. The disclosure for this sale can be found here. Insiders have sold 333,310 shares of company stock worth $16,857,255 over the last three months. Corporate insiders own 0.76% of the company’s stock.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be given a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.88%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s payout ratio is presently 83.47%.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.